BIOMAT Database Logo BIOMAT Database Logo

Type IIa hyperlipoproteinemia and HLA-A and B antigens: no association. 1984

F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard

One hundred unrelated patients with type IIa hyperlipoproteinemia have been investigated for their HLA-A and B antigens and compared to 171 normal controls. This study does not support the significant increase of HLA-B17 and Bw35 previously reported by others.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D015234 HLA-A Antigens Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts. Antigens, HLA-A,HLA-A,Antigens, HLA A,HLA A Antigens
D015235 HLA-B Antigens Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes. Antigens, HLA-B,HLA-B Antigen,HLA-B,Antigen, HLA-B,Antigens, HLA B,HLA B Antigen,HLA B Antigens

Related Publications

F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
Type IIa hyperlipoproteinemia and the HLA system.
January 1978, Tissue antigens,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
[Type IIA hyperlipoproteinemia].
November 1977, Pediatriia,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
[Clofibrate in type IIa hyperlipoproteinemia. Reduction of apolipoprotein B (author's transl)].
August 1978, MMW, Munchener medizinische Wochenschrift,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
Tuberous xanthomas in type IIA hyperlipoproteinemia.
January 2002, Indian journal of dermatology, venereology and leprology,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
[Moyamoya syndrome with hyperlipoproteinemia type IIa].
January 1979, Ceskoslovenska neurologie a neurochirurgie,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
Phytosterolemia and type IIa hyperlipoproteinemia with tuberous xanthomas.
January 1981, Journal of the American Academy of Dermatology,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
Platelet function and antithrombins in hyperlipoproteinemia type IIa.
May 1981, Thrombosis research,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
Type IIa hyperlipoproteinemia masquerading as cerebrotendinous xanthomatosis.
December 1989, Journal of the neurological sciences,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
[Hyperlipoproteinemia type IIa with known cholesterol values].
February 1985, Medicina clinica,
F Dufosse, and M E Ferraz, and J Goudemand, and J P Rouget, and P Dewailly, and J Jaillard
[Secondary hyperlipoproteinemia type IIa in anorexia nervosa].
January 1977, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
Copied contents to your clipboard!